Loren Data's SAM Daily™

SAMDAILY.US - ISSUE OF JUNE 15, 2023 SAM #7870
SOLICITATION NOTICE

65 -- US Certified Heat Inactivated Fetal Bovine Serum 500mL Lot # 2661794P

Notice Date

6/13/2023 2:38:56 PM
 

Notice Type

Presolicitation
 

NAICS

325414 — Biological Product (except Diagnostic) Manufacturing
 

Contracting Office

NATIONAL INSTITUTES OF HEALTH NIAID BETHESDA MD 20892 USA
 

ZIP Code

20892
 

Solicitation Number

NOI-NIAID-23-2175832
 

Response Due

6/20/2023 1:00:00 PM
 

Archive Date

07/05/2023
 

Point of Contact

DIANA ROHLMAN, Phone: 4063639366, Laura Grey, Phone: 4063759812
 

E-Mail Address

diana.rohlman@nih.gov, laura.grey@nih.gov
(diana.rohlman@nih.gov, laura.grey@nih.gov)
 

Description

This is a Notice of Intent, not a request for proposal. �The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Life Technologies to procure Fetal Bovine Serum (FBS), 80 units of Lot # 2661794P Manufacturer � Gibco US Certified Heat Inactivated FBS 500ml CAT # 10082147 QTY: 80 MUST BE Lot # 2661794P with 4 shipments each of 20 bottles on 08/7/23, 12/04/23, 04/08/24, and 06/10/24� SHIP TO ADDRESS:� NIH, CLINICAL CENTER, 10 CENTER DRIVE, BETHESDA, MD 20814� FOB DESTINATION� The HIV Immunovirology Section of the Laboratory of Immunoregulation at NIAID is ordering fetal bovine serum that will be used for conducting cell culture work using clinical specimens collected from ongoing clinical trials. The LIR is requesting 80 bottles of heat inactivated fetal bovine serum with Lot # 2661794P for use in our long-standing research projects within the area of HIV/AIDS Pathogenesis. It is not possible to change the brand at this point as doing so will introduce variables to our on-going research and clinical trials. The fetal bovine serum will be used to make cell culture media to cultivate CD4 and CD8+ T cells from a number of ongoing clinical trials (NIAID under clinical protocol #02-I-0202 and 18-I-0115) and other related studies (Role of Viral Reservoirs in Pathogenesis of HIV Disease (Z01-AI000851-05) to understand how the host immune system controls HIV viral replication without antiretroviral drugs.� Any capability statements submitted must address meeting all of the requirements, delivery schedule, and the guarantee of the specific Lot # 2661794P for this Fetal Bovine Serum for all four (4) shipments.� OTHER LOT #�S ARE NOT ACCEPTABLE AND WILL NOT BE CONSIDERED. The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. �All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-NIAID-23-2175832) to Diana Rohlman, diana.rohlman@nih.gov by 4:00 pm eastern standard time Tuesday, June 20, 2023. �All responses received by the closing date of this synopsis will be considered by the Government. �A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government. �
 

Web Link

SAM.gov Permalink
(https://sam.gov/opp/d9c242f8de4f423b89234fa55ae2ffdc/view)
 

Place of Performance

Address: Bethesda, MD 20814, USA

Zip Code: 20814

Country: USA
 

Record

SN06714429-F 20230615/230613230117 (samdaily.us)
 

Source

SAM.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's SAM Daily Index Page |